



# PROGRAMME - Sunday 19 October 2008

<b>0800–1900</b>	<b>Registration (Main Foyer)</b>	
	<b>Riverside Theatre</b>	<b>Meeting Room 4</b>
	<b>HSANZ</b>	<b>ANZSBT</b>
<b>0900–1030</b>	<b>Molecular Basis of Haematological Disorders</b> <i>Sponsored by Celgene</i> Chair – Dr Peter Mollie <b>Prof John Shaughnessy, USA:</b> (0900) <i>Molecular-based risk stratification of multiple myeloma: Are we there yet?</i>  <b>Prof Anthony Green, UK:</b> (0945) <i>Molecular pathogenesis of the myeloproliferative disorders</i>	<b>Critical Bleeding</b> <i>Sponsored by CSL</i> Chair – Dr Nicole Staples <b>Prof Jean-François Hardy, Canada:</b> (0900) <i>Massive transfusion and coagulopathy: pathophysiology and clinical implications</i>  <b>Dr Stephen Langford, WA:</b> (0945) <i>Critical bleeding: Retrieval Service perspective</i>  <b>Dr Sudhakar Rao, WA:</b> (1005) <i>Critical bleeding: Trauma Service perspective</i>
<b>1030–1100</b>	<b>MORNING TEA (Exhibition Hall)</b>	
<b>1100–1200</b>	<b>Acute Leukaemia</b> Chair – Dr Peter Browett <b>A/Prof Lynda Campbell, VIC:</b> (1100) <i>Unravelling the complexity of chromosome abnormalities in acute myeloid leukaemia</i>  <b>Prof Martin Tallman, USA:</b> (1130) <i>New strategies in acute promyelocytic leukaemia</i>	<b>Landmark Studies</b> Chair – Dr Peter Flanagan <b>Prof Morris Blajchman, Canada :</b> (1100) <i>Landmark studies that have changed the practice of transfusion medicine: The top 10 RCTs</i>
<b>1200–1300</b>	<b>Barry Firkin Oration (Riverside Theatre)</b> Chair – A/Prof Chris Ward <b>Professor Alex Gallus, SA:</b> <i>Evidence-based medicine: wish-fulfilment or search for excellence?</i>	
<b>1300–1400</b>	<b>LUNCH (Exhibition Hall)</b>	
	<b>ANZSBT AGM (Meeting Room 4) HSANZ Nursing Group AGM (Meeting Room 1)</b>	
<b>1400–1530</b>	<b>Bone Marrow Transplantation Combined HSANZ / BMTSAA / Nurses Symposium</b> Chair – A/Prof Richard Herrmann <b>Prof Joachim Deeg, USA:</b> (1400) <i>Timing of transplantation and choice of conditioning in MDS and MPD</i>  <b>Dr Ian Lewis, SA:</b> (1445) <i>Therapeutic applications of mesenchymal stem cells in haemopoietic stem cell transplantation</i>	<b>Molecular Advances in Transfusion Medicine</b> Chair – A/Professor David Roxby <b>Dr Marion Reid, USA:</b> (1400) <i>Experience using DNA-based assays to predict blood group antigens</i>  <b>Dr Paul Metcalfe, UK:</b> (1445) <i>Platelet antigens</i>
<b>1530–1600</b>	<b>AFTERNOON TEA (Exhibition Hall)</b>	

# PROGRAMME - Sunday 19 October 2008

0800–1900	Meeting Rooms 2/3	Meeting Room 1	Meeting Room 7
	ASTH	NURSES	BMTSAA
0900–1030	<b>Hormones, Thrombophilia and Thrombosis</b>	<b>Quality of Life</b>	<b>Education Session</b>
	Chair – Prof Hatem Salem	Chair – Tracy King	Chair – Dr Christine Hicks
	<b>Prof Frits Rosendaal, The Netherlands: (0900)</b> <i>Female hormones and venous thrombosis</i>	<b>Ms Julie Wilkes, WA: (0900)</b> <i>Home chemotherapy</i>	<b>Dr Louise Winteringham, WA: (0900)</b> <i>From stem cells to blood cells</i>
	<b>Prof David Lane, UK: (0930)</b> <i>Update on the Protein C anticoagulation pathway</i>	<b>A/Prof Anne Williams, WA: (0930)</b> <i>QOL – concepts and measurement : The patient's perspective</i>	<b>Dr Stuart Hodgetts, WA: (0940)</b> <i>Improved functional recovery after transplantation of human bone marrow stromal stem cells from spinal cord injured patients into the acute and chronic injured rat spinal cord</i>
	<b>Dr Quintin Hughes, WA: (1000)</b> <i>Protein C &amp; S gene mutations and regulation by hormones</i>	<b>Ms Moira Stephens, NSW: (1000)</b> <i>What can qualitative research do for me?</i>	<b>BMTSAA Announcements (1020)</b>
1030–1100	<b>MORNING TEA (Exhibition Hall)</b>		
1100–1200	<b>Anticoagulation</b>	<b>Apheresis Update</b>	<b>Technical Session</b>
	Chair – Dr Paul Ockelford	Chair – Shannon Ellis & Julie Tovey	Chair – Sue Carnoutsos & Gail Lazzaro
	<b>Dr Sanjeev Chunilal, NZ: (1100)</b> <i>The future of new antithrombotics</i>	<b>Mrs Jo-Anne Moodie, VIC: (1100)</b> <i>Immunoabsorption for ABO incompatible renal transplants</i>	<b>Dr Cheryl Hutchins, QLD: (1100)</b> <i>Cryopreservation</i>
	<b>Prof Hatem Salem, VIC: (1130)</b> <i>Warfarin reversal: How long do we have to wait to get it right?</i>	<b>Ms Susan Price, Mr Andrew McCutchan and Ms Joanne Kanakis, QLD: (1130)</b> <i>On the road to accreditation with a little help from our friends</i>	<b>Dr Scott Ragg, TAS:</b> <i>Single platform viable CD34 +ve cell enumeration</i>
		<b>BMTSAA AGM (1215)</b>	
1200–1300	<b>Barry Firkin Oration (Riverside Theatre)</b>		
	Chair – A/Prof Chris Ward		
	<b>Professor Alex Gallus, SA:</b> <i>Evidence-based medicine: wish-fulfilment or search for excellence?</i>		
1300–1400	<b>LUNCH (Exhibition Hall)</b>		
1400–1530	<b>ANZSBT AGM (Meeting Room 4)</b>	<b>HSANZ Nursing Group AGM (Meeting Room 1)</b>	
	<b>Von Willebrand Disease</b>	<b>Combined HSANZ/BMTSAA/ Nurses Symposium</b>	<b>Combined HSANZ/BMTSAA/ Nurses Symposium)</b>
	Chair - Prof Ross Baker		
	<b>Prof David Lillicrap, Canada: (1400)</b> <i>Molecular aspects of vWD</i>		
<b>Dr Simon Brown, QLD: (1440)</b> <i>Testing for vWD</i>			
<b>Dr Scott Dunkley, NSW: (1505)</b> <i>Treatment of von Willebrand Disease</i>			
1530-1600	<b>AFTERNOON TEA (Exhibition Hall)</b>		

# PROGRAMME - Sunday 19 October 2008

	Riverside Theatre	Meeting Room 4
	HSANZ	ANZSBT
1600-1730	<b>Chronic Lymphocytic Leukaemia</b> <i>Sponsored by Roche</i> Chair – Prof Stephen Mulligan <b>Prof Nicholas Chiorazzi, USA: (1600)</b> <i>The cell of origin in chronic lymphocytic leukaemia</i>	<b>Transfusion Risks</b> Chair – Dr Lynn Aston <b>A/Prof Simon Brown, WA: (1600)</b> <i>Anaphylaxis: diagnosis and management</i>
	<b>Prof Michael Keating and Prof William Plunkett, USA: (1635)</b> <i>The yin and yang of therapeutic research in CLL</i>	<b>Dr Krishna Badami, NZ: (1625)</b> <i>Transfusion-related anaphylaxis: investigations and management</i>
	<b>A/Prof Andrew Roberts, VIC: (1710)</b> <i>BH3 mimetic antagonists of BCL-2 – potential new therapy for CLL and lymphoproliferative diseases</i>	<b>Mr Clive Seed, WA: (1700)</b> <i>Transfusion-transmissible viral infections</i>
1730-1900	<b>Welcome Reception (Ballroom Foyer)</b>	
1930		

# PROGRAMME - Sunday 19 October 2008

	Meeting Rooms 2/3	Meeting Room 1	Meeting Room 7
	<b>ASTH</b>	<b>NURSES</b>	<b>BMTSAA</b>
<b>1600-1730</b>	<b>How Do I Treat?</b>  Chair – Dr Tim Brighton <b>A/Prof Chris Ward, NSW: (1600)</b> <i>Antiphospholipid antibody syndrome</i>	<b>Non-Malignant Haematology</b>  Chair – Moira Stephens <b>Dr Kathryn Robinson, SA: (1600)</b> <i>Iron deficiency anaemia: the neglected diagnosis- update and management</i>	<b>Discussion Forum on FACT Requirements (commences 1530)</b>  <b>Impending Regulation and NPAAC Requirements 2008</b> Panel: <b>Dr Scott Ragg, TAS</b> <b>Prof Jeff Szer, Vic</b> <b>Mr Justin Gerace, WA</b> <b>Mr Geoffrey Webb, WA</b> <b>Mr Craig Wright, NSW</b>
	<b>Dr Claire McLintock, NZ: (1630)</b> <i>PE in pregnancy</i>	<b>Ms Clare Bell, WA: (1630)</b> <i>A practical approach to haemophilia</i> <b>Ms Karen Flounders, WA: (1650)</b> <i>A practical approach to thrombosis</i>	<b>Poster Discussion (1700)</b> Chair – Judy Stevens
	<b>Dr Harry Gibbs, QLD: (1700)</b> <i>Venous thrombosis in unusual sites</i>	<b>Ms Jill Smith, WA: (1710)</b> <i>Establishing a haemophilia nursing program</i>	
<b>1730-1900</b>	<b>Welcome Reception (Ballroom Foyer)</b>		
<b>1930</b>	<b>BMTSAA DINNER</b>		

# PROGRAMME - Monday 20 October 2008

<b>0800–1900</b>	<b>Registration</b>	
	<b>Riverside Theatre</b>	<b>Meeting Room 4</b>
	<b>HSANZ</b>	<b>ANZSBT</b>
<b>0830–1000</b>	<b>Free Communications 1 - 4</b>	<b>Presidential Symposium</b>
		Chair – Dr Peter Flanagan
	<b>Free Communications 1:</b> Chair – Kathy Crosier Haemopoiesis <b>Meeting Room 6</b> Abstracts #01 – 06	<b>0830</b> <b>O25</b> <b>Catherine Hyland</b> <i>Clinical evaluation of non-invasive prenatal RHD genotyping of the fetus</i>
	<b>Free Communications 2:</b> Chair – Yiu Lam Kwan Chronic Lymphocytic Leukaemia <b>Meeting Room 7</b> Abstracts #07 – 12	<b>0845</b> <b>O26</b> <b>Geoff Simon</b> <i>Development of an on-line "Ordering and Receiving Blood System" (ORBS)</i>
	<b>Free Communications 3:</b> Chair – Michael Harvey Acute Leukaemia <b>Riverside Theatre</b> Abstracts #13 – 18	<b>0900</b> <b>O27</b> <b>Peta Dennington</b> <i>A pilot study on the incidence of HLA class I, class II and HNA antibodies in blood donors</i>
	<b>Free Communications 4:</b> Chair – Dr Andrew McQuillan Autologous Stem Cell Transplantation <b>Meeting Room 8</b> Abstracts #19 – 24  (See pages 48 – 49)	<b>0915</b> <b>O28</b> <b>David Roxby</b> <i>Acute coagulopathy in trauma</i>
		<b>0930</b> <b>O29</b> <b>Kristen Glenister</b> <i>Microparticles in stored red cell concentrates: a proteomic approach</i>
<b>1000–1030</b>	<b>MORNING TEA (Exhibition Hall)</b>	
<b>1030–1130</b>	<b>New Insights Into Old Problems</b>	<b>Cardiac and Obstetric Transfusion Challenges</b>
	Chair – Prof L Bik To	Chair – Dr Amanda Thomson
	<b>Prof John Olynyk, WA:</b> (1030) <i>Hereditary haemochromatosis update</i>	<b>Prof Jean-François Hardy, Canada:</b> (1030) <i>Cardiac surgery transfusion issues</i>
	<b>Prof John Shaughnessy, USA:</b> (1100) <i>The role of DKK1-mediated suppression of Wnt/β-catenin in multiple myeloma</i>	<b>Dr Andrew Barr, WA:</b> (1100) <i>Obstetric haemorrhage</i>
<b>1130–1230</b>	<b>Carl de Gruchy Oration (Riverside Theatre)</b> Chair - Dr David Gottlieb <b>A/Professor Alison Street, VIC:</b> <i>Haemophilia, History and Hope</i>	
<b>1230–1330</b>	<b>LUNCH (Exhibition Hall)</b> <b>ASTH AGM (Meeting Room 4) BMTSANZ AGM (Meeting Room 6)</b>	

# PROGRAMME - Monday 20 October 2008

0800–1900	Meeting Rooms 2/3	Meeting Room 1	Meeting Room 9
	ASTH	NURSES	
0830–1000	<b>Free Communications 1</b> <b>Thrombosis and Anticoagulation</b> Chair – Dr Simon McRae <b>0830 O30</b> <b>Claire McLintock</b> <i>Pregnancy outcome in women with mechanical heart valves treated with enoxaparin</i> <b>0845 O31</b> <b>Ross Baker</b> <i>Risk assessment for peri-operative management of patients on Warfarin therapy</i> <b>0900 O32</b> <b>Julia Phillips</b> <i>Antithrombin deficiency in pregnancy: thromboprophylaxis and venous thromboembolism (VTE) incidence in 16 pregnancies</i> <b>0915 O33</b> <b>Peter Tan</b> <i>The use of a prothrombin-complex concentrate (Prothrombinex-VF®) in medical and surgical patients – a review of a single institution's experience</i> <b>0930 O34</b> <b>Sophie Lee</b> <i>Survival in patients with malignancy and venous thromboembolism varies significantly with tumour subtype and thrombotic load</i> <b>0945 O35</b> <b>Kate Burbury</b> <i>Warfarin reversal, for elective surgical procedures, using low dose intravenous vitamin K: Impact on vitamin K-dependent factor levels</i>	<b>Free Communications 1</b> Chair – Catherine Wood & Angela Booth <b>0830 O36</b> <b>Julija Sipavicius</b> <i>Got the protocol – how to achieve compliance? E-learning lessons as a tool to improve compliance to clinical protocols</i> <b>0845 O37</b> <b>Maree Bransdon</b> <i>Changing practice - making it safer</i> <b>0900 O38</b> <b>Wendy Jar</b> <i>To enteral feed or not</i> <b>0915 O39</b> <b>Susan Hyde</b> <i>Cryotherapy to prevent oral mucositis in patients receiving high dose Melphalan for autologous stem cell transplantation</i> <b>0930 O40</b> <b>Simon Kuzyl</b> <i>The assessment of a senior haematology nurse performing un-sedated bone marrow biopsies in a large tertiary cancer centre</i> <b>0945 O41</b> <b>Fran Owen</b> <i>AMD3100 for patients failing haemopoietic stem cell (HSC) mobilisation - the Illawarra Experience</i>	<b>Free Communications 2</b> Chair – Robyn Kovac & Anne Kilcullen <b>0830 O42</b> <b>Kirstin Bubner</b> <i>Telephone triage in cancer nursing</i> <b>0845 O43</b> <b>Samantha Schembri</b> <i>Evaluation of the Leukaemia Foundation Disease Specific DVD series developed to facilitate education and support programmes to empower patients and their families living with leukaemia, lymphoma, myeloma and related blood disorders</i> <b>0900 O44</b> <b>Tracy King</b> <i>You can talk about it and people understand. Telephone support groups: psychosocial support for myeloma patients in NSW</i> <b>0915 O45</b> <b>Jan Chapple</b> <i>Myelodysplastic syndromes (MDS) - the value of transfusion plans and transfusing at higher haemoglobins</i> <b>0930 O46</b> <b>Linley Bielby</b> <i>Nursing time required to administer a red cell transfusion – does the allocated time accurately reflect reality?</i> <b>0945 O47</b> <b>Kim Creighton &amp; Rosita Van Kuilenburg</b> <i>Twenty units of blood and counting...</i>
1000–1030	<b>MORNING TEA (Exhibition Hall)</b>		
1030–1130	<b>Venous Thrombosis</b> Chair – Dr Douglas Coghlan <b>Prof Frits Rosendaal, The Netherlands: (1030)</b> <i>Epidemiology of venous thrombosis</i> <b>Dr Tim Brighton, NSW: (1100)</b> <i>New strategies for predicting VTE recurrence and optimizing treatment duration</i>	<b>New Approaches</b> Chair – Susan Hyde <b>Mr Wayne Epton, WA: (1030)</b> <i>Nutritional challenges in haematology patients</i> <b>Ms Sue Hyde, WA: (1100)</b> <i>Nurse practitioners – the Western Australian experience</i>	
1130–1230	<b>Carl de Gruchy Oration (Riverside Theatre)</b> Chair - Dr David Gottlieb <b>A/Professor Alison Street, VIC: Haemophilia, History and Hope</b>		
1230–1330	<b>LUNCH (Exhibition Hall)</b> <b>ASTH AGM (Meeting Room 4) BMTSANZ AGM (Meeting Room 6)</b>		

# PROGRAMME - Monday 20 October 2008

	Riverside Theatre	Meeting Room 4
	HSANZ	ANZSBT
1330–1500	<b>Combined HSANZ/ASTH Presidential Symposium</b> Chair – Dr David Gottlieb & A/Prof Chris Ward <b>1330 O48</b> <b>Peter Mollee</b> <i>Sequential treatment with Rituximab and CHOP chemotherapy in B-cell post-transplant lymphoproliferative disease (PTLD) – will risk stratified sequential treatment become the new standard in therapy?</i> <b>1345 O49</b> <b>Andrew Spencer</b> <i>Thalidomide consolidation further improves the progression free survival (PFS) of multiple myeloma (MM) patients that have already achieved a complete (CR) or very good partial response (VGPR) following a single ASCT procedure</i> <b>1400 O50</b> <b>Leighton Clancy</b> <i>Adoptively transferred CMV specific T cells exhibit multiple effector functions associated with protective immunity including the concurrent production of multiple cytokines and cytolytic activity</i> <b>1415 O51</b> <b>David Ritchie</b> <i>The level of glycolytic metabolism of AML blasts as a predictor of drug sensitivity and clinical prognosis</i> <b>1430 O52</b> <b>Elizabeth Gardiner</b> <i>Increasing shear rates cause shedding of platelet glycoprotein (GP)VI</i> <b>1445 O53</b> <b>Hatem Salem</b> <i>Warfarin anticoagulation can be effectively reversed with Prothrombinex®-VF without the need for fresh frozen plasma</i>	<b>Contingency Planning</b> Chair – Dr Erica Wood <b>Ms Stephanie Gunn, ACT: (1330)</b> <i>Australia's National Blood Supply Contingency Plan</i> <b>Dr Simon Towler, WA: (1350)</b> <i>Australia's National Haemovigilance Project</i> <b>Prof Morris Blajchman, Canada : (1420)</b> <i>Protecting the blood supply from emerging pathogens: the role of pathogen inactivation</i>
1500-1530	<b>AFTERNOON TEA (Exhibition Hall)</b>	
1530-1630	<b>Lymphoma</b> Chair – Dr Maher Gandhi & Robert Bird <b>Dr Simon Rule, UK: (1530)</b> <i>Should we further centralise haematology services?</i> <b>Dr Wyndham Wilson, USA: (1600)</b> <i>Lymphomatoid granulomatosis (LYG) and other EBV lymphoproliferative disorders</i>	<b>Solid Organ Transplantation</b> Chair – TBC <b>Dr Shlomo Cohnen, VIC: (1530)</b> <i>Renal transplantation: HLA, ABO and other challenges</i> <b>Dr Chris Hogan, VIC: (1600)</b> <i>Solid organ transplantation: transfusion laboratory considerations</i>
1630-1730	<b>POSTERS (Rear of Exhibition Hall)</b>	
1730-1830	<b>Masterclasses (HSANZ)</b> <b>Meeting Room 6</b> Chair – Dr Gavin Cull <b>Prof Michael Keating, USA:</b> <i>Management of CLL in 2008</i> <b>Meeting Room 7</b> Chair – Prof Jeff Szer <b>Prof Joachim Deeg, USA:</b> <i>Conditioning therapy for allogeneic stem cell transplantation</i>	<b>Masterclasses (ANZSBT)</b> <b>Meeting Room 4</b> Panel <b>Prof Morris Blajchman, Canada</b> <b>Prof Jean-François Hardy, Canada:</b> <i>Age of red cells for transfusion: is fresh best?</i>

# PROGRAMME - Monday 20 October 2008

	Meeting Rooms 2/3	Meeting Room 1
	<b>ASTH</b>	<b>NURSES</b>
<b>1330–1500</b>	<b>Combined HSANZ/ASTH Presidential Symposium</b>	<b>Transplantation</b>
		Chair – Krys Emery & Barbara O'Callaghan
		<b>Prof Jeff Szer, VIC: (1330)</b> <i>Graft-versus-host disease: Prevention, treatment, acute, chronic, still a problem</i>
		<b>Dr Sarah Steed, WA: (1400)</b> <i>ALL – classification and treatment in young adults</i>
		<b>Ms Meg Plaster, WA (1430)</b> <i>HEADSS UP: Recognising and responding to the needs of young people receiving treatment for haematological malignancies</i>
<b>1500–1530</b>	<b>AFTERNOON TEA (Exhibition Hall)</b>	
<b>1530–1630</b>	<b>Challenges in Haemophilia Care</b>	<b>Cord Blood</b>
	Chair – Prof Ross Baker	Chair – Rosita Van Kuilenberg
	<b>Prof David Lillicrap, Canada: (1530)</b> <i>Gene transfer to cure haemophilia</i>	<b>Ms Jenny Forrester, VIC: (1530)</b> <i>The role of the Cord Blood Bank midwife ...</i>
	<b>Dr Mark Smith, NZ: (1600)</b> <i>Why do inhibitors develop in haemophilia?</i>	<b>Prof Ken Bradstock, NSW: (1600)</b> <i>The expanding role of cord blood transplantation</i>
<b>1630–1730</b>	<b>POSTERS (Rear of Exhibition Hall)</b>	
<b>1730–1830</b>	<b>Masterclasses (ASTH)</b>	<b>Current Issues in Nursing: Workshop &amp; Open Floor Discussion</b>
	<b>Meeting Room 2/3</b> Chair – Grace Gilmore	<i>Venous Access Devices: What is the Role of the Nurse?</i>
	<b>Prof David Lane, UK</b> <i>Publishing without perishing</i>	<b>Meeting Room 1</b> Chair – Krys Emery
		<b>Ms Cathy Smyth, WA</b>
		<b>Ms Barbara O'Callaghan, WA</b>

# PROGRAMME - Monday 20 October 2008

Monday 20 October – 0830-1000

## HSANZ Free Communications 1: Haemopoiesis

Meeting Room 6

**0830** **001**  
**Derek Hart**

*CD300f triggering modifies myeloid cell function*

**0845** **002**  
**Simon Harrison**

*Comparison of in vivo migration patterns of different DC preparations from a single donor using a novel PET agent and flow cytometry on excised lymph nodes*

**0900** **003**  
**Derek Hart**

*Depletion of host CD122+ cells facilitates widespread skeletal multiple myeloma engraftment in NOD/SCID recipients*

**0915** **004**  
**Bojiang Shen**

*BMP-2 enhances TGF- $\beta$ 3 - mediated chondrogenic differentiation of human bone marrow multipotent mesenchymal stromal cells (BM MSCs) in-vitro*

**0930** **005**  
**Lisa Kaminskis**

*Interaction of human allogeneic mesenchymal stromal cells with normal B cells and B cells from patients with autoimmune disorders*

**0945** **006**  
**M Farid Johan**

*Transcriptional silencing of the suppressor of cytokine signalling-1 (SOCS-1) by aberrant methylation of Exon 2 in acute myeloid leukaemia and human haematopoietic cell lines*

Monday 20 October – 0830-1000

## HSANZ Free Communications 2: Chronic Lymphocytic Leukaemia

Meeting Room 7

**0830** **007**  
**Stephen Mulligan**

*Significant variation in absolute lymphocyte count (ALC) for the diagnosis of chronic lymphocytic leukaemia (CLL) with 2008 guidelines*

**0845** **008**  
**Stephen Mulligan**

*Autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. analysis of patients presenting in Sydney Northern Metropolitan Area*

**0900** **009**  
**Peter Gambell**

*CLL MRD flow cytometric testing using the International Standardised Approach*

**0915** **010**  
**Stephen Fuller**

*Susceptibility to chronic lymphocytic leukaemia in a large multi-generational family*

**0930** **011**  
**Peter Mollee**

*CCL2 and CXCL2 enhance long-term survival of primary chronic lymphocytic leukaemia cells in vitro*

**0945** **012**  
**Jane Freeman**

*Immunoglobulin G (IgG) subclass deficiency in chronic lymphocytic leukaemia*

Monday 20 October – 0830-1000

## HSANZ Free Communications 3: Acute Leukaemia

Riverside Theatre

**0830** **013**  
**Shane Gangatharan**

*Acute myeloid leukaemia (AML) in Western Australia (WA) 1991-2005: a retrospective population-based study of 830 patients regarding epidemiology, cytogenetics, treatment and outcome*

**0845** **014**  
**Colin Phipps Diong**

*Acute promyelocytic leukaemia: A 10 Year experience in a single institution*

**0900** **015**  
**Helen Weston**

*Outcomes of treatment of adult acute lymphoblastic leukemia with hyper-CVAD in Brisbane*

**0915** **016**  
**Julie Wilkes**

*Ciprofloxacin prophylaxis during HyperCVAD chemotherapy at home: a retrospective cohort analysis*

**0930** **017**  
**Tse-Chieh Teh**

*Case report: the eradication of Monosomy 7 in therapy-related myelodysplastic syndrome/acute myeloid leukaemia with LBH589*

**0945** **018**  
**Jeff Szer**

*Eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH): The Australian experience*

# PROGRAMME - Monday 20 October 2008

Monday 20 October – 0830-1000

## HSANZ Free Communications 4: Autologous Stem Cell Transplantation

### Meeting Room 8

---

**0830** **019**  
**Fiona Kwok**

*Autologous stem cell transplantation (auto-SCT) in older patients with multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). A single centre study.*

---

**0845** **020**  
**Phillip Wearden**

*Reduction in emesis with addition of aprepitant to standard anti-emetic therapy in patients undergoing high dose chemotherapy and stem cell transplantation*

---

**0900** **021**  
**Sushrut Patil**

*Neurological involvement by systemic diffuse large B cell non-Hodgkin lymphoma (DLBCL) has an extremely poor outcome following high dose chemotherapy and autologous stem cell rescue (ASCT): germinal centre (GC) phenotype may have a better disease free survival*

---

**0915** **022**  
**Alhossain Khalafallah**

*Quality of life assessment of patients with multiple myeloma after autologous stem cell transplantation (ASCT)*

---

**0930** **023**  
**Raymond Hiep Banh**

*Oral CID chemotherapy followed by autologous stem cell transplant (ASCT) is an effective therapy in the initial management of multiple myeloma*

---

**0945** **024**  
**Shane Gangatharan**

*131I-Rituximab BEAM conditioning in autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma*

---

# PROGRAMME - Tuesday 21 October 2008

0800–1900	Registration	
	Riverside Theatre	Meeting Room 4
	HSANZ	ANZSBT
0830–1000	<b>Normal and Malignant Haemopoiesis</b> <i>Sponsored by Novartis</i> Chair – Dr David Joske <b>Prof Anthony Green, UK:</b> (0830) <i>Management of MPD in the JAK-2 era</i>  <b>Dr Warren Alexander, VIC:</b> (0910) <i>Mutagenesis screens for genetic dissection of haematopoiesis</i>  <b>Dr Susan Branford, SA:</b> (0935) <i>Molecular monitoring in clinical practice for CML</i>	<b>Free Communications 1</b>  Chair – Ms Linley Bielby  <b>0830</b> O54 <b>Peta Dennington</b> <i>The use of intravenous immunoglobulin (IVIg) in haematological conditions in Australia</i>  <b>0845</b> O55 <b>Kathryn Robinson</b> <i>Database linkage to establish the frequency of underlying iron deficiency anaemia (IDA) in transfused patients</i> <i>Iron deficiency anaemia (IDA) – a neglected diagnosis and common reason for transfusion (and over transfusion) in stable patients</i>  <b>0900</b> O56 <b>Penelope Hassell</b> <i>A review of alloimmune neonatal cases (ANN) from 2003-2008</i>  <b>0915</b> O57 <b>Louise Phillips</b> <i>Establishment of new national registries for Thrombotic thrombocytopenic purpura and Neonatal alloimmune thrombocytopenia: sharing information to build knowledge</i>  <b>0930</b> O58 <b>Suzi Rishworth</b> <i>Fresh frozen plasma usage in six New Zealand hospitals</i>  <b>0945</b> O59 <b>Peta Dennington</b> <i>Audit of cryoprecipitate use in two Sydney teaching hospitals: combining retrospective and prospective approaches</i>
1000–1030	<b>MORNING TEA (Exhibition Hall)</b>	
1030–1130	<b>Free Communications 5-8</b>  <b>Free Communications 5:</b> <b>Riverside Theatre</b> Chair – Daniel Owens Lymphoma Abstracts #066-069  <b>Free Communications 6:</b> <b>Meeting Room 6</b> Chair – Humphrey Pullon Chronic Myeloid Leukaemia/Myeloproliferative Disease Abstracts #070-073  <b>Free Communications 7:</b> <b>Meeting Room 7</b> Chair – Prof Derek Hart Immunotherapy Abstracts #074-077  <b>Free Communications 8:</b> <b>Meeting Room 8</b> Chair – Dr Julian Cooney Graft-versus-host Disease Abstracts #078-081  (See page 54)	<b>RCPA Transfusion QAP and ANZSBT Standing Committees</b>  RCPA Transfusion QAP <b>Dr Bronwyn Williams</b>  ANZSBT Standing Committees <b>A/Prof David Roxby</b> <b>Mr David Peterson</b> <b>Dr Nicole Staples</b>

# PROGRAMME - Tuesday 21 October 2008

0800–1900	Registration	
	Meeting Rooms 2/3	Meeting Room 1
	ASTH	ANZSBT
0830–1000	<b>New Understanding of Blood Coagulation</b> Chair – Dr Robert Andrews <b>Prof David Lane, UK:</b> (0830) <i>The central role of Thrombin in haemostasis</i> <b>Dr Robert Andrews, VIC:</b> (0910) <i>A factor XII dependent coagulation pathway feeds back from thrombin generation and requires platelet activation</i> <b>Dr Justin Hamilton, VIC:</b> (0935) <i>Protease-activated receptors as targets for novel anti-platelet agents</i>	<b>Free Communications 2</b> Chair – Ms Gina Aitken <b>0830</b> <b>O60</b> <b>Margaret Veale</b> <i>The age of red blood cells (RBCs) at the time of blood donation and storage influence the generation of microparticles positive for Glycophorin A (GPA), CD55 and CD59</i> <b>0845</b> <b>O61</b> <b>Mary Zmijarevic</b> <i>RhD genotyping of foetal DNA extracted from maternal plasma, Goettingen, Germany</i> <b>0900</b> <b>O62</b> <b>Siobhan Cross</b> <i>Prospective determination of blood group frequency of a multiethnic patient population in Western Sydney</i> <b>0915</b> <b>O63</b> <b>Damien Heathcote</b> <i>Development and validation of antibody screening cells specifically designed for Asian populations – the first example of the addition of peptide antigens to human red cells using KODETM technology</i> <b>0930</b> <b>O64</b> <b>Tim Carroll</b> <i>The value of routine process controls in improving safety in immunohaematology testing – 3 years experience</i> <b>0945</b> <b>O65</b> <b>Suzanne Candy</b> <i>Contact activation markers Factor Xlla, Prothrombin Fragments F1 and 2, C3a and sC5b-9 in Buffy coat pooled platelets stored in SSP+</i>
1000–1030	<b>MORNING TEA (Exhibition Hall)</b>	
1030–1130	<b>ASTH Free Communications 2: New Technologies</b> Chair – Dr Murray Adams <b>1030</b> <b>O82</b> <b>Jennifer Curnow</b> <i>Reduced fibrinolysis and increased fibrin generation are found in patients with the Antiphospholipid Syndrome (APLS)</i> <b>1045</b> <b>O83</b> <b>Lisa Lincz</b> <i>Endogenous thrombin potential (ETP) as a novel method for characterization of procoagulant snake venoms</i> <b>1100</b> <b>O84</b> <b>Brian Dale</b> <i>Global assessment of protein S deficiency by ProC Global and calibrated automated thrombin generation assays</i> <b>1115</b> <b>O85</b> <b>Natalie Pecheniuk</b> <i>Plasma fibronectin levels are elevated in patients with venous thromboembolism</i>	

# PROGRAMME - Tuesday 21 October 2008

	Riverside Theatre	Meeting Room 4
	HSANZ	ANZSBT
1130–1230	<b>Ruth Sanger Oration (Riverside Theatre)</b> Chair - Dr Peter Flanagan <b>Dr John Rowell, QLD:</b> <i>External quality assurance in transfusion in Australia</i>	
1230–1330	<b>LUNCH (Exhibition Hall)</b> <b>HSANZ AGM (Meeting Room 4)</b>	
1330–1500	<b>Lymphoproliferative Disease</b> Chair – A/Prof Mark Hertzberg & Bryone Kuss <b>Prof Nicholas Chiorazzi, USA:</b> (1330) <i>Role of the B-cell receptor in CLL</i>	<b>Platelet Alloimmunisation</b> Chair – Dr Andrew Barr <b>Dr Paul Metcalfe, UK:</b> (1330) <i>Platelet alloimmunisation</i>
	<b>Dr Wyndham Wilson, USA:</b> (1415) <i>Molecular biomarkers in diffuse large B-cell lymphoma</i>	<b>Prof James Bussel, USA:</b> (1415) <i>Clinical management of fetal and neonatal alloimmune thrombocytopenia</i>
1500-1530	<b>AFTERNOON TEA (Exhibition Hall)</b>	
1530-1630	<b>Clinical BMT</b> Chair – David Ritchie <b>Prof Joachim Deeg, USA:</b> (1530) <i>Post-transplant malignancies: risk factors related to patient, donor and transplant regimen</i>	<b>Rare Blood</b> Chair – Dr Richard Charlewood <b>Dr Marion Reid, USA:</b> (1530) <i>Provision of rare blood</i>
	<b>Dr Ian Hewson, VIC:</b> (1600) <i>Oral complications of BMT</i>	<b>Mr Brian Fisher, WA:</b> (1605) <i>Rare blood: The Australian perspective</i>
1630-1730	<b>Masterclasses (HSANZ)</b> <b>Meeting Room 7</b> Chair – Prof Andrew Spencer <b>Prof John Shaughnessy, USA:</b> <i>How to create a multidisciplinary translational cancer research program: The Myeloma Institute for Research and Therapy as a model</i> <b>Meeting Room 6</b> Chair – Andrew Roberts <b>Prof Martin Tallman, USA:</b> <i>Management of acute lymphoblastic leukaemia</i>	<b>Masterclasses (ANZSBT)</b> <b>Meeting Room 8</b> Panel <b>Prof James Bussel, USA</b> <b>Dr Paul Metcalfe, UK</b> <b>Dr Marion Reid, USA:</b> <i>Complex cases: red cell and platelet alloimmunisation</i>
1900	<b>CONFERENCE DINNER (Matilda Bay Reserve, coaches depart Perth Convention Centre at 1845)</b>	

# PROGRAMME - Tuesday 21 October 2008

	Meeting Room 2/3	Meeting Room 1
	<b>ASTH</b>	<b>Diagnostic Laboratory Science</b>
1130–1230	<b>Ruth Sanger Oration (Riverside Theatre)</b> Chair - Dr Peter Flanagan Dr John Rowell, QLD: <i>External quality assurance in transfusion in Australia</i>	
1230–1330	<b>LUNCH (Exhibition Hall)</b> <b>HSANZ AGM (Meeting Room 4)</b>	
1330–1500	<b>Arterial Thrombosis</b> Chair - Dr Tim Brighton Dr Ashley Irish, WA: (1330) <i>Thrombosis in AV fistula</i> Dr Andre Samson, VIC: (1400) <i>What the hell is tPA doing in my brain?</i> Dr Jamie Rankin, WA: (1430) <i>Aspirin and clopidogrel resistance - what does it mean?</i>	<b>Morphology and QAP</b>  <b>Facilitators:</b> A/Prof Surender Juneja, VIC Dr Lesley Survela, NSW
1500-1530	<b>AFTERNOON TEA (Exhibition Hall)</b>	
1530-1630	<b>Coagulation Issues in Snakes and Children</b> Chair – Dr James Price Dr Geoffrey Isbister, NSW: (1530) <i>Snake bite coagulopathy: antivenom, FFP or nothing at all</i>  Prof Paul Monagle, VIC: (1600) <i>Anticoagulation in children</i>	
1630-1730	<b>Masterclasses (ASTH)</b> <b>Meeting Room 1</b> Chair – Dr Mark Smith Prof David Lillicrap, Canada: <i>Diagnosis and management of mild bleeding disorders</i>	
1900	<b>CONFERENCE DINNER (Matilda Bay Reserve, coaches depart Perth Convention Centre at 1845)</b>	

# PROGRAMME - Tuesday 21 October 2008

Tuesday 21 October – 1030-1130

## HSANZ Free Communications 5:

### Lymphoma

Riverside Theatre

**1030** **066**

**Anna Johnston**

*Retreatment with rituximab +/- chemotherapy in 178 patients with relapsed and refractory B-cell lymphomas: a single institution study*

**1045** **066**

**Stefan Peinert**

*Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia*

**1100** **068**

**Andrew McQuillan**

*Radioimmunotherapy of newly diagnosed adioimmunotherapy of newly diagnosed, advanced, low-grade lymphoma with <sup>131</sup>I-Rituximab: The initial study*

**1115** **069**

**Stefan Peinert**

*Complete remission on 18FDG-PET prior to autologous stem cell transplantation predicts superior event free survival of patients with relapsed or refractory Hodgkin lymphoma*

Tuesday 21 October – 1030-1130

## HSANZ Free Communications 6:

### Chronic Myeloid Leukaemia/Myeloproliferative Disease Meeting Room 6

**1030** **070**

**Yen Phuong Dang**

*Patient-specific IC50 assays in imatinib-resistant CML patients are variable and may be clinically relevant*

**1045** **071**

**David Ross**

*High rate of sustained complete molecular response of chronic myeloid leukaemia after withdrawal of Imatinib: Progress of the ALLG CML8 Study*

**1100** **072**

**Deborah White**

*The IC50 assay is predictive of molecular response and indicative of optimal dose in de-novo CML patients*

**1115** **073**

**Emmanuelle Fantino**

*Targeted JAK2 inhibitors for myeloproliferative diseases*

Tuesday 21 October 1030-1130

## HSANZ Free Communications 7:

### Immunotherapy

Meeting Room 7

**1030** **074**

**Emily Blyth**

*Prophylactic infusion of donor derived CMV-specific cytotoxic T lymphocytes in haemopoietic stem cell transplant (HSCT) recipients*

**1045** **075**

**Ross Brown**

*T Cell Control of Monoclonal Gammopathies : Further Evidence from Waldenstrom's Macroglobulinaemia*

**1100** **076**

**Maher Gandhi**

*Mechanisms underlying the selective impairment of EBNA1-specific effector T-cells observed in PTLD delete full stop*

**1115** **077**

**Paul Neeson**

*Gene-modified CD8+ T cells undergo functional polarization to effector and central memory cells in response to antigen exposure.*

Tuesday 21 October – 1030-1130

## HSANZ Free Communications 8:

### Graft-versus-host Disease

Meeting Room 8

**1030** **078**

**Ines Chamakhi**

*Efficacy of salvage therapy for acute myeloid leukaemia relapsing after allogeneic stem cell is dependant on the induction of graft-versus-host disease*

**1045** **079**

**David Ritchie**

*Prospective study of capsule endoscopy for the diagnosis of gastro-intestinal graft-versus-host disease*

**1100** **080**

**Mary Sartor**

*Reconstitution of regulatory T cells following allogeneic stem cell transplantation and association with Graft-versus-host disease*

**1115** **081**

**David Gottlieb**

*The effect of immunosuppressive drugs on the expansion and function of antigen specific T cells*

# PROGRAMME - Wednesday 22 October 2008

0800–1900	Registration		
	Riverside Theatre	Meeting Room 4	Meeting Rooms 2/3
	HSANZ	ANZSBT	ASTH
0830–1000	Free Communications 9-12	Free Communications 3	ASTH Free Communications 3: Bleeding Disorders
		Chair – Dr Ellen Maxwell	Chair – Dr Scott Dunkley
	<p><b>Free Communications 9:</b> Chair – Paul Cannell Leukaemia Biology <b>Meeting Room 6</b> Abstracts #086-091</p> <p><b>Free Communications 10:</b> Chair – Dr Brad Augustson Myeloma <b>Riverside Theatre</b> Abstracts #092-097</p> <p><b>Free Communications 11:</b> Chair – Dr Glen Kennedy Allogeneic Stem Cell Transplantation <b>Meeting Room 7</b> Abstracts #098-0103</p> <p><b>Free Communications 12:</b> Chair – Dr Jill Finlayson Iron, Haemoglobin and Flow Cytometry <b>Meeting Room 1</b> Abstracts #0104-0109</p> <p>(See pages 56 – 57)</p>	<p><b>0830</b> <b>Romi Sinha</b> <i>Massive transfusion in trauma</i></p> <p><b>0845</b> <b>Rebecca Howman</b> <i>Extent and timing of dilutional coagulopathy and thrombocytopenia in massively transfused obstetric patients</i></p> <p><b>0900</b> <b>Louise Phillips</b> <i>Adherence to transfusion protocols and the use of recombinant activated Factor VII</i></p> <p><b>0915</b> <b>Mary Zmijarevic</b> <i>Monitoring the temperature of red cells stored between 2 to 6°C and the time taken to reach 10°C at room temperature</i></p> <p><b>0930</b> <b>Ralph Green</b> <i>Teaching transfusion and transplantation science in an information communication technology (ICT) enabled wet laboratory environment</i></p> <p><b>0945</b> <b>Erica Wood</b> <i>Transfusing a unit of red cells – what does it really cost in Australia?</i></p>	<p><b>O110</b> <b>0830</b> <b>Ian Hewson</b> <i>Oral surgery with minimum factor support in haemophilia and vWD patients</i></p> <p><b>O111</b> <b>0845</b> <b>Ketan Bavishi</b> <i>Retrospective analysis of Desmopressin responses in patients with type 1 and type 2 von Willebrand Disorder and haemophilia A In South Australia</i></p> <p><b>O112</b> <b>0900</b> <b>Deepak Singhal</b> <i>A report on acquired haemophilia A in South Australia from 1998 to 2008</i></p> <p><b>O113</b> <b>0915</b> <b>Huy Tran</b> <i>A single tertiary centre experience with inhibitors in paediatric patients with severe haemophilia</i></p> <p><b>O114</b> <b>0930</b> <b>Simon Brown</b> <i>Low incidence of high titre FVIII inhibitors in children with severe haemophilia A while only treated with an intermediate purity FVIII concentrate (BPL 8Y). Experience from five centres in the UK</i></p> <p><b>O115</b> <b>0945</b> <b>Rebecca Howman</b> <i>A multi-centre retrospective study to assess the safety and efficacy of Biostate® in children with von Willebrand's Disease (vWD)</i></p>
1000–1100	MORNING TEA AND ANNOUNCEMENT OF PRIZES (Exhibition Hall)		
1100–1230	<p><b>Meeting Room 4</b></p> <p><b>ALLG Symposium</b></p> <p>Chair – Prof Andrew Spencer</p> <p><b>Prof Martin Tallman, USA: (1100)</b> <i>Novel therapeutic targets in acute myeloid leukaemia</i></p> <p><b>Dr Simon Rule, UK: (1145)</b> <i>How do we manage mantle cell lymphoma in 2008?</i></p>	<p><b>Riverside Theatre</b></p> <p><b>Thrombocytopenia Combined ANZSBT/ASTH Symposium</b> <i>Sponsored by Amgen</i></p> <p>Chair – Dr Claire McLintock</p> <p><b>Prof James Bussel, USA: (1100)</b> <i>Thrombopoietic agents in patients with ITP</i></p> <p><b>Dr Benjamin Kile, VIC: (1140)</b> <i>The molecular control of platelet life span</i></p> <p><b>Dr Simon McRae, SA: (1205)</b> <i>Heparin induced thrombocytopenia</i></p>	<p><b>Combined ANZSBT/ASTH Symposium</b></p>

# PROGRAMME - Wednesday 22 October 2008

Wednesday 22 October 0830-1000

## HSANZ Free Communications 9: Leukaemia Biology

Meeting Room 6

**0830** **086**

**Faith Kwa**

*Synergistic interactions between DNA-damaging agents and HDACi's induce upregulation of BCL6 in the promyelocytic leukaemia cell line, HL-60*

**0845** **087**

**Alec Morley**

*Rapid isolation of DNA breakpoints in leukaemia by bottleneck PCR*

**0900** **088**

**Melanie Sulda**

*Dipeptidyl peptidase (DP) expression in B-cell chronic lymphocytic leukaemia (B-CLL)*

**0915** **089**

**Kylie Mason**

*The BH3 mimetic compound ABT-737, synergises with standard chemotherapy to induce apoptosis in chronic lymphocytic leukaemia (CLL)*

**0930** **090**

**Philip Saunders**

*Combining RAD001 (Everolimus) with Bortezomib induces synergistic killing in precursor-B acute lymphoblastic leukemia*

**0945** **091**

**Philip Saunders**

*Dose escalated RAD001 (Everolimus) enhances chemosensitivity in precursor-B acute lymphoblastic leukemia, through a JNK dependent impairment of cell cycle arrest, in response to DNA damage or microtubule disruption*

Wednesday 22 October 0830-1000

## HSANZ Free Communications 10: Myeloma

Riverside Theatre

**0830** **092**

**Andrew Spencer**

*A new generation IAP inhibitor (IAPi) induces apoptosis of human myeloma cells and synergises with conventional and novel anti-myeloma therapeutics*

**0845** **093**

**Andrew Spencer**

*Clinical and immunohistochemical features associated with a response to Bortezomib in patients with multiple myeloma*

**0900** **094**

**Stefan Peinert**

*Targeting Lewis Y-positive multiple myeloma and acute myeloid leukaemia with gene-modified T cells demonstrating memory phenotype*

**0915** **095**

**Paul Neeson**

*in vitro efficacy of agonistic antibody to TRAIL-R1 (Mapatumumab) and low dose Bortezomib in multiple myeloma*

**0930** **096**

**Simon Harrison**

*Safety and efficacy of Bortezomib combined with the deacetylase inhibitor Romidepsin in patients with relapsed or refractory multiple myeloma: interim results of a phase I/II trial*

**0945** **097**

**Julian Cooney**

*Bone turnover, bone mineral density and other characteristics in post-transplant myeloma patients*

Wednesday 22 October 0830-1000

## HSANZ Free Communications 11: Allogeneic Stem Cell Transplantation

Meeting Room 7

**0830** **098**

**Nalini Pati**

*No bones about it: Determining the optimal aspiration volume during bone marrow harvest*

**0845** **099**

**Biju George**

*Higher incidence of CMV reactivation following fludarabine based reduced intensity conditioning transplants – a retrospective comparison with myeloablative transplants*

**0900** **0100**

**Kenneth Bradstock**

*A retrospective comparison of the outcome of single versus double unrelated umbilical cord blood units for allogeneic transplantation in adults with advanced hematological malignancies*

**0915** **0101**

**Anthony Schwarer**

*Can otherwise incurable haematological malignancies be cured by KIR-ligand mismatched haploidentical stem cell transplantation (haploH SCT)? – The Alfred Hospital experience*

**0930** **0102**

**Peter Tan**

*Delayed relapse and long-term follow-up of allogeneic bone marrow transplantation for chronic myeloid leukaemia*

**0945** **0103**

**Shane Bleakley**

*Plasma exchange as treatment of transplantation-associated thrombocytopenic microangiopathy (TA-TMA): Effect of concomitant acute GVHD on efficacy and outcome*

# PROGRAMME - Wednesday 22 October 2008

Wednesday 22 October 0830-1000

## HSANZ Free Communications 12: Iron, Haemoglobin and Flow Cytometry

### Meeting Room 1

---

**0830** **0104**

**Alhossain Khalafallah**

*A prospective randomised trial of intravenous iron therapy versus oral iron for iron deficiency anaemia in pregnant women*

---

**0845** **0105**

**Alhossain Khalafallah**

*Compliance and tolerability of iron therapy during pregnancy*

---

**0900** **0106**

**Stephen Mulligan**

*Epidemiology of thalassaemia and haemoglobinopathy in New South Wales*

---

**0915** **0107**

**Jill Finlayson**

*The incidence of haemoglobin disorders in refugees migrating to Western Australia – a 5 year retrospective study, 2003–2007*

---

**0930** **0108**

**Kate Burbury**

*The role of flow cytometry in myelodysplastic syndromes (MDS)*

---

**0945** **0109**

**Nalini Pati**

*Flow cytometry as a diagnostic tool for hereditary spherocytosis - Westmead Hospital experience*

